Palavras-chave
quimioterapia
Pediatría
cisplatino
ifosfamida
imatinib
metrotexato
Como Citar
Resumo
A quimioterapia desempenha um papel crucial no tratamento do câncer pediátrico, mas o seu uso está associado a uma variedade de efeitos colaterais, incluindo toxicidade renal. A importância reside no fato de que a toxicidade renal é um dos efeitos adversos mais desafiadores de se manejar devido ao seu potencial de causar danos cumulativos com o uso repetitivo. Geralmente, a toxicidade renal apenas reverte parcialmente após a descontinuação do agente quimioterápico, limitando assim o seu uso no tratamento do câncer e afetando o prognóstico oncológico do paciente. O objetivo principal desta revisão narrativa é fornecer uma visão abrangente e atualizada dos efeitos adversos renais de diferentes agentes quimioterápicos, bem como os potenciais mecanismos subjacentes da nefrotoxicidade e as estratégias de prevenção implementadas, com foco em complexos de platina, ifosfamida, inibidores de tirosina quinase como o imatinibe e metotrexato.
Foi realizada uma pesquisa eletrônica nas bases de dados PubMed, UpToDate, ClinicalKey, Google Scholar e Scopus utilizando os seguintes termos MeSH: "Nefrotoxicidade", "Quimioterapia", "Pediatria", "Cisplatina", "Carboplatina", "Ifosfamida", "Imatinibe" e "Metotrexato". Foram incluídas séries de casos, artigos de revisão e revisões sistemáticas sobre a toxicidade renal associada ao uso de quimioterapia em pediatria.
Antonio Ruggiero C, Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi R. REVIEW Renal toxicity and chemotherapy in children with cancer. 2017; Available from: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.13388
Ruggiero A, Ariano A, Triarico S, Capozza MA, Romano A, Maurizi P, et al. Cisplatin-induced nephrotoxicity in children: what is the best protective strategy? Journal of Oncology Pharmacy Practice. 2021 Jan 1;27(1):180–6.
Carboplatino en oncopediatría [Internet]. [cited 2023 May 20]. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75312004000200008
Ruebner RL, Copelovitch L, Evageliou NF, Denburg MR, Belasco JB, Kaplan BS. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: Case series and review of the literature. Pediatric Nephrology. 2014;29(5):863–9.
Salie R, Silver R. Uncommon or Delayed Adverse Events Associated With Imatinib Treatment for Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2010 Oct 1;10(5):331–5.
Ruggiero A, Trombatore G, Triarico S, Arena R, Ferrara P, Scalzone M, et al. Platinum compounds in children with cancer: Toxicity and clinical management. Anticancer Drugs. 2013 Nov;24(10):1007–19.
Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode [17]. Nature. 1965;205(4972):698–9.
Barton CD, Pizer B, Jones C, Oni L, Pirmohamed M, Hawcutt DB. Identifying cisplatin-induced kidney damage in paediatric oncology patients.
Vitae [Internet]. [cited 2023 Jul 11]. Available from: https://vitae.ucv.ve/index_pdf.php?module=articulo&rv=143&n=5995&m=2&e=5997
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin Nephrotoxicity. Toxins 2010, Vol 2, Pages 2490-2518 [Internet]. 2010 Oct 26 [cited 2023 May 20];2(11):2490–518. Available from: https://www.mdpi.com/2072-6651/2/11/2490/htm
Role of vascular congestion in cisplatin-induced acute renal failure in the rat - PubMed [Internet]. [cited 2023 May 20]. Available from: https://pubmed.ncbi.nlm.nih.gov/1316576/
Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther [Internet]. 2009 Oct [cited 2023 May 20];86(4):396. Available from: /pmc/articles/PMC2746866/
Vinke JSJ, Heerspink HJL, De Borst MH. Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus. Curr Opin Nephrol Hypertens [Internet]. 2019 Jul 1 [cited 2023 May 20];28(4):321–7. Available from: https://pubmed.ncbi.nlm.nih.gov/30958403/
Orlov SN, Koltsova S V., Kapilevich L V., Dulin NO, Gusakova S V. Cation-chloride cotransporters: regulation, physiological significance, and role in pathogenesis of arterial hypertension. Biochemistry (Mosc) [Internet]. 2014 [cited 2023 May 20];79(13):1546–61. Available from: https://pubmed.ncbi.nlm.nih.gov/25749164/
Santos NAG, Catão CS, Martins NM, Curti C, Bianchi MLP, Santos AC. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol [Internet]. 2007 Jul [cited 2023 May 20];81(7):495–504. Available from: https://pubmed.ncbi.nlm.nih.gov/17216432/
Erdlenbruch B, Nier M, Kern W, Hiddemann W, Pekrun A, Lakomek M. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. European Journal of Clinical Pharmacology 2001 57:5 [Internet]. 2001 Jun 16 [cited 2023 May 21];57(5):393–402. Available from: https://link.springer.com/article/10.1007/s002280100319
Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson ADJ. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors. Eur J Cancer [Internet]. 2009 Dec 1 [cited 2023 May 21];45(18):3213–9. Available from: http://www.ejcancer.com/article/S0959804909005140/fulltext
Ashrafi F, Mortazavi M, Nematbakhsh M. The Prevention of Cisplatin-Induced Nephrotoxicity: A General Consensus Statement of a Group of Oncologist-Hematologists, Adult and Pediatric Nephrologists, Radiation Oncologists, Clinical Pathologists, Clinical Pharmacologists, and Renal Physiologists on Cisplatin Therapy in Cancer Patients. Int J Prev Med [Internet]. 2022 [cited 2023 Jul 10];13(1). Available from: https://pubmed.ncbi.nlm.nih.gov/35392316/
Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol [Internet]. 2018 Feb 1 [cited 2023 May 21];31(1):15–25. Available from: https://link.springer.com/article/10.1007/s40620-017-0392-z
Flombaum CD. Hypomagnesemia Associated With Cisplatin Combination Chemotherapy. Arch Intern Med [Internet]. 1984 Dec 1 [cited 2023 May 21];144(12):2336–7. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/605127
View of Fanconi syndrome due to chemotherapeutic agents: A case series and literature review | Revista Colombiana de Nefrología [Internet]. [cited 2023 Jul 10]. Available from: https://revistanefrologia.org/index.php/rcn/article/view/606/1040
Alhaqas, Ahmed. SAT-027 CISPLATIN NEPHROTOXICITY IN A PATIENT WITH CERVICAL CANCER WITH ACQUIRED TYPE 2 RENAL TUBULAR ACIDOSIS: REVIEW OF LITERATURE AND CASE REPORT. 2020;
Cis-platinum and distal renal tubule toxicity - PubMed [Internet]. [cited 2023 May 21]. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.javeriana.edu.co/2986064/
Hamdi T, Latta S, Jallad B, Kheir F, Alhosaini MN, Patel A. Cisplatin-induced renal salt wasting syndrome. South Med J [Internet]. 2010 Aug [cited 2023 May 21];103(8):793–9. Available from: https://pubmed.ncbi.nlm.nih.gov/20622742/
Gilbert RD, Stanley LK, Fowler DJ, Angus EM, Hardy SA, Goodship TH. Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab. Clin Kidney J. 2013 Aug 1;6(4):421–5.
Duffy EA, Fitzgerald W, Boyle K, Rohatgi R. Nephrotoxicity: Evidence in Patients Receiving Cisplatin Therapy. Clin J Oncol Nurs [Internet]. 2018 Apr 1 [cited 2023 Feb 18];22(2):175–83. Available from: https://pubmed.ncbi.nlm.nih.gov/29547601/
Órgano oficial de la Asociación Latinoamericana de Nefrología Pediátrica Í N d i c e Miembro de la iNterNAtioNAL PediAtric NePhroLogy AssociAtioN (iPNA).
English, MW, al. Dose-related nephrotoxicity of carboplatin in children. 1999;
Carboplatin-related toxicity in children with cancer.
MANUAL SEOM DE CUIDADOS CONTINUOS 3a EDICIÓN. 2019;
Skinner R. Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. Pediatric Nephrology. 2018 Feb 1;33(2):215–25.
Skinner R, Sharkey IM, Pearson ADJ, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. Journal of Clinical Oncology. 1993;11(1):173–90.
Ifosfamida: Antineoplásicos | Vademécum Académico de Medicamentos | AccessMedicina | McGraw Hill Medical [Internet]. [cited 2023 May 25]. Available from: https://accessmedicina.mhmedical.com/content.aspx?bookid=1552§ionid=90371322
Rossi R. Nephrotoxicity of ifosfamide--moving towards understanding the molecular mechanisms. Nephrol Dial Transplant [Internet]. 1997 [cited 2023 May 25];12(6):1091–2. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.javeriana.edu.co/9198030/
Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, et al. Long-term evaluation of ifosfamide-related nephrotoxicity in children. Journal of Clinical Oncology. 2009 Nov 10;27(32):5350–5.
Loebstein R, Koren G. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics. 1998;101(6).
R S, SJ C, MC S. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children’s Cancer Study Group. Br J Cancer [Internet]. 2000 Apr 27 [cited 2023 May 29];82(10):1636–45. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.javeriana.edu.co/10817497/
Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer. 2007 Apr;48(4):447–52.
Aleksa K, Halachmi N, Ito S, Koren G. Renal ontogeny of ifosfamide nephrotoxicity. J Lab Clin Med [Internet]. 2004 [cited 2023 May 29];144(6):285–93. Available from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.javeriana.edu.co/15614250/
Shore R, Greenberg M, Geary D, Koren G. Iphosphamide-induced nephrotoxicity in children. Pediatr Nephrol [Internet]. 1992 Mar [cited 2023 May 29];6(2):162–5. Available from: https://pubmed.ncbi.nlm.nih.gov/1571213/
Etiology and clinical manifestations of renal tubular acidosis in infants and children - UpToDate [Internet]. [cited 2023 May 29]. Available from: https://www.uptodate.com/contents/etiology-and-clinical-manifestations-of-renal-tubular-acidosis-in-infants-and-children/print
Foà R, Chiaretti S. Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. New England Journal of Medicine. 2022 Jun 23;386(25):2399–411.
Flynn JP, Gerriets V. Imatinib. xPharm: The Comprehensive Pharmacology Reference [Internet]. 2022 Jul 2 [cited 2023 May 29];1–7. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551676/
Salie R, Silver R. Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2010;10(5):331–5.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Manuel Alejandro Nieto González; ; David José Coca León , Rodrigo Alberto Heredia Ramírez, July Andrea Russi Noguera, Gabriela Negrete Tobar; Karen Lizeth Cuervo Martínez; María Beatriz Valdivieso Márquez, Natalia Manrique Marín, María Baquero Fonseca